This program summarizes the most important antitrust developments in the healthcare industry in the second and third quarters of 2024. Panelists discuss topics like pharmaceuticals, group purchasing organizations, providers, healthcare technology, medical devices, and health insurers. Key cases include Vistalik, which shapes how courts approach reverse payment claims, and Lipitor, which underscores the challenges of certifying class actions in generic delay cases. The panel also covers the Sedibi case, where the Ninth Circuit overturned a lower court's decision on jury instructions and the use of pre-2006 evidence.
